Metamark Genetics said today it inked a collaborative deal to act as the exclusive worldwide sales agent for Hologic‘s (NSDQ:HOLX) Progensa PCA3 assay, designed to test for prostate cancer.
The Progensa PCA3 is the 1st urine-based molecular test of its kind, according to Metamark. The test is designed to quantify cancer-specific overexpression of prostate cancer antigen 3 RNA in patient samples.
“The Progensa PCA3 assay is an exceptionally beneficial tool that accurately classifies ‘true negative’ patients with a high negative predictive value of 90%, enabling the urologist and the patient to make a more informed repeat biopsy decision. This additional information can significantly alleviate the clinical consequences and cost of proceeding with an unnecessary repeat biopsy,” Metamark chief medical officer Dr. Jerome Richie said in a press release.
The Progensa PCA3 won FDA premarket approval in 2012 for use with Hologic’s semi-automated DTS system, and can provide “clinically meaningful information” to improve prediction of repeat biopsy outcomes for men who’ve ahd 1 or more negative biopsies.
The deal positions both companies to develop a 2nd-generation assay for early detection of prostate cancer with Hologic’s Panther instrument system, which Metamark will have license to co-promote in specified territories upon completion.
“Metamark’s success in delivering high-value diagnostic and prognostic tests for the prostate oncology market provides a strong foundation for this collaboration. We very much look forward to leveraging Metamark’s proven urological cancer care expertise as we seek to expand our footprint in the field of prostate oncology,” Hologic diagnostic solutions prez Tom West said in a prepared statement.
Financial and other terms of the collaborative agreement were not disclosed.
“Hologic has demonstrated tremendous leadership within the diagnostic space, providing greater certainty through innovative technology, and improving patient lives. Metamark is eager to proceed with this exciting partnership to further advance prostate cancer detection, and continue our mission to supply more comprehensive information to urologists across the complete prostate cancer continuum,” Metamark CEO Ken Weg said in prepared remarks.
The post Metamark to sell Hologic’s Progensa prostate cancer test appeared first on MassDevice.
from MassDevice http://ift.tt/1Rb3U5B
Cap comentari:
Publica un comentari a l'entrada